← boardnext 2028-03-31
KYNB
Kyntra Biodistress 2/10 · well-funded / low risk$7.21-1%today-42% from 52w high
Lead: metastatic castration-resistant prostate cancer · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$95M
Runway
4.5 yrs
Shares 1y
+0%
Price & events
-19.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
+0.1%
1W
+4.9%
1M
+0.3%
3M
-19.6%
6M
-6.4%
1Y
-77.1%
2Y
-97.9%
5Y
-99.2%
All
Overview
- Market Cap
- $29.21M
- Volume
- 4.40K
- 52 Week Range
- $6.46 – $12.43
- Total Shares
- 4.05M
- Float Shares
- 3.56M
- Short %
- 2.76%
- % Held by Insiders
- 2.02%
- % Held by Institutions
- 25.57%
- RVOL
- 0.15x
- Beta
- 0.97
Pipeline stages · 1 programs
FG-3246
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-03-31 Estimated 50% readout ~2028-05-15 | Phase 2 | FG-3246 | Metastatic Castration-Resistant Prostate Cancer | — | recruiting |
Catalyst news & presentations · 11
- second half of 2026Guided 55%readoutPhase 2FG-3246 · Interim results from Phase 2 monotherapy trial of FG-3246 expected.SEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-02partnershipReceived final $4M holdback from AstraZeneca for sale of China operations.SEC 8-K
- first quarter of 2026conferencedata presentationsecondaryPhase 1/2FG-3246 · Topline results from investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide to be presented at ASCO GU.SEC 8-K
- second half of 2025readoutPhase 2FG-3246 · Topline results from Phase 2 combination trial with enzalutamideSEC 8-K
- 2025-11-06partnershipReceived $6.4M holdback payment from AstraZenecaSEC 8-K
- third quarter of 2025trial initiationsecondaryPhase 2FG-3246 · Phase 2 monotherapy trial initiation in mCRPCSEC 8-K
- 2025-08-29partnershiproxadustat · Completed sale of FibroGen China to AstraZeneca for ~$220MSEC 8-K
- 2025-08-29partnershipClosed sale of China operations to AstraZeneca for $220MSEC 8-K
- 2Q 2025trial initiationsecondaryPhase 2FG-3246 · Initiation of Phase 2 monotherapy trial in mCRPCSEC 8-K
- 2025-02-19partnershiproxadustat · Sale of FibroGen China to AstraZeneca for ~$160M; AstraZeneca acquires roxadustat rights in China, Hong Kong, MacaoSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $39 (+441% upside) · 2 analysts
- 2026-07-07OppenheimerOutperform
- 2026-06-09Rodman & RenshawBuy
- 2025-09-24HC Wainwright & Co.Buy
- 2025-08-07HC Wainwright & Co.Buy
Competitors — metastatic castration-resistant prostate cancer
- NVSEFNOVARTIS AG$292.0B · D3
- AMGNAMGEN INC$195.4B · D3
- PFEPFIZER INC$142.2B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- OLMAOlema Pharmaceuticals, Inc.$990M · D4
- ACETAdicet Bio, Inc.$78M · D5
- INMBInmune Bio, Inc.$47M · D5
- KAPAKairos Pharma, LTD.$6M · D7
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-16Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support Zone - Counter Trend Trade - dars.gov.et
- 2026-07-14If You Invested $1,000 in KYNTRA BIO INC (KYNB) - Stock Titan
- 2026-07-05Net margin % of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
- 2026-06-25Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Miss Reflects Continued R&D Investment - CEO Earnings Statement - dars.gov.et
- 2026-06-25Kyntra Bio Inc. (KYNB) Edges Higher on Above-Average Volume, Tests Key Resistance Zone - ETH Profile - dars.gov.et
- 2026-06-13Kyntra Bio Inc. Q1 2026 Earnings: Pre‑Revenue Biotech Posts Wider‑Than‑Expected Loss, Stock Gains 5.47% - Positive Surprise Momentum - Bölüm Sonu Canavarı
- 2026-06-11Kyntra Bio Presents New Roxadustat Data on Improvements in - GlobeNewswire
- 2026-06-09Kyntra Bio receives final $4.0M holdback from AstraZeneca, completes China sale proceeds - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.